Research summary ·
Tumor lysis syndrome in breast cancer: a systematic review of the literature.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This review looked at tumor lysis syndrome in breast cancer. This syndrome is life-threatening. It is well known in blood cancers but seen as rare in solid tumors. In breast cancer it had been seen only in case reports. New drug classes may add new risks. The team searched PubMed, Embase and Web of Science. The search ran from January 2000 to June 2026. It covered case reports and case series. Diagnosis was checked against Cairo-Bishop criteria.
What they found
20 cases from 20 publications were found. One more case showed successful prevention. All had advanced disease. Liver metastases were present in 11 of 20. Triggers included endocrine therapy, HER2-targeted therapy, chemotherapy and radiotherapy. Overall deaths were 10 of 20. Endocrine therapy cases had the highest death rate, at 3 of 4. Most of those drugs were aromatase inhibitors.
What it means for patients
The authors say tumor lysis syndrome in breast cancer is rare but carries high mortality. They view endocrine therapy, mainly aromatase inhibitors, as an underappreciated trigger. They note that use of new targeted agents is growing.
Why it is not certain yet
The data are case reports and case series only. They cannot show how often the syndrome occurs. The groups by trigger were very small.
Source
Tumor lysis syndrome in breast cancer: a systematic review of the literature.
PubMed · PMID 42952660We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Metastatic breast cancer publications